Compound details
Mukurozidiol
| Compound ID | CDAMM02573 |
|---|---|
| Common name | Mukurozidiol | IUPAC name | 9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxyfuro[3,2-g]chromen-7-one |
| Molecular formula | C17H18O7 |
| Retention time | 4.61 |
|---|---|
| Adduct | [2M+Na]+ |
| Actual mz | 691.201 | Theoretical mz | 691.199 |
| Error | 3.01 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 6.0548 |
| Inchi key | PKRPFNXROFUNDE-UHFFFAOYNA-N |
|---|---|
| Smiles | O=C1OC=2C(OCC(O)C(O)(C)C)=C3OC=CC3=C(OC)C2C=C1 |
| Superclass | Phenylpropanoids and polyketides |
| Class | Coumarins and derivatives |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P43166 | CA7 | Carbonic anhydrase VII | T37541 | SEA |
| P22460 | KCNA5 | Voltage-gated potassium channel subunit Kv1.5 | T17569 | SEA |
| P22001 | KCNA3 | Voltage-gated potassium channel subunit Kv1.3 | T76914 | SEA |
| Q92952 | KCNN1 | Small conductance calcium-activated potassium channel protein 1 | T11911 | SEA |
| Q9H2S1 | KCNN2 | Small conductance calcium-activated potassium channel protein 2 | T86271 | SEA |
| Q09470 | KCNA1 | Voltage-gated potassium channel Kv1.1 | T85272 | SEA |
| Q96RP8 | KCNA7 | Voltage-gated potassium channel Kv1.7 | T84737 | SEA |
| P22459 | KCNA4 | Voltage-gated A-type potassium channel | T15665 | SEA |
| P16389 | KCNA2 | Voltage-gated potassium channel Kv1.2 | T19492 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T17569 | DI0030 | Angina pectoris | [ICD-11: BA40] | P22460 | KCNA5 |
| T76914 | DI0198 | Idiopathic inflammatory myopathy | [ICD-11: 4A41] | P22001 | KCNA3 |
| T76914 | DI0351 | Psoriasis | [ICD-11: EA90] | P22001 | KCNA3 |
| T76914 | DI0352 | Psoriatic arthritis | [ICD-11: FA21] | P22001 | KCNA3 |
| T11911 | DI0285 | Myelopathy | [ICD-11: 8B42] | Q92952 | KCNN1 |
| T86271 | DI0285 | Myelopathy | [ICD-11: 8B42] | Q9H2S1 | KCNN2 |